Danaher Corp (DHR)

AINewsWire Editorial Coverage : As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice (“GMP”) requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this…

AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice (GMP) requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]

Although the S&P 500 is down 2.8% over the past six months, Danaher’s stock price has fallen further to $190.75, losing shareholders 9.3% of their capital. T...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Danaher (NYSE:DHR) and its peers. Th...

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making

As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

BALA CYNWYD, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings

As AI uncertainty weighs on stocks, consider loading up on these dividend-growth blue chips instead.

On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash

In a move that has sent shockwaves through the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180.00 per share in an all-cash transaction. The deal, valued at approximately $9.

Masimo supplies noninvasive monitoring tech to hospitals and care providers, serving both medical and consumer health markets worldwide.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Every quarter, we get to see what the best of the best have bought and sold.

In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents

As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]

The deal will entail Danaher paying $180 per share for Masimo, reflecting about 18 times Masimo’s projected 2027 earnings before interest, taxes, depreciation, and amortization.

Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”).

Danaher is reportedly set to acquire Masimo, with the deal expected to be announced as early as Tuesday.